Nexien BioPharma (NXEN) 10-Q 8 Feb 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2021	Feb. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	000-55320
Entity Registrant Name	NEXIEN BIOPHARMA, INC.
Entity Central Index Key	0001625288
Entity Tax Identification Number	26-2049376
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4340 E Kentucky Ave.
Entity Address, Address Line Two	Suite 206
Entity Address, City or Town	Glendale
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80246
City Area Code	(303)
Local Phone Number	495-7583
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		60,022,196

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Jun. 30, 2021
Current Assets
Cash	$ 2,942	$ 18,041
Prepaids		7,500
Total current assets	2,942	25,541
Total Assets	2,942	25,541
Current Liabilities
Accounts payable and accrued expenses	6,563	6,375
Due to officer	35,000	20,000
Convertible notes payable - related party, net of discount of $41,196 at December 31, 2021 and $52,059 at June 30, 2021	23,804	12,941
Total current liabilities	65,367	39,316
Stockholders’ (Deficit)
Preferred stock - $.0001 par value; 10,000,000 authorized; none issued
Common stock - $.0001 par value; 200,000,000 shares authorized; 56,772,196 shares and 55,772,196 shares issued and outstanding at December 31, 2021 and June 30, 2021, respectively	5,677	5,577
Additional paid in capital	10,545,904	10,476,004
Stock payable	35,000	35,000
Common stock subject to forfeiture		(223,255)
Accumulated deficit	(10,649,006)	(10,307,101)
Total Stockholders’ (Deficit)	(62,425)	(13,775)
Total Liabilities and Stockholders’ (Deficit)	$ 2,942	$ 25,541

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Jun. 30, 2021
Statement of Financial Position [Abstract]
Debt instrument net of discount	$ 41,196	$ 52,059
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	56,772,196	55,772,196
Common stock, shares outstanding	56,772,196	55,772,196

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue
Operating expenses
Professional fees	11,440	7,400	17,480	22,990
General and administrative	202,056	818,798	310,955	1,864,500
Total operating expenses	213,496	826,198	328,435	1,887,490
Other income (expense)
Interest expense - related	(1,296)	(527)	(2,607)	(655)
Amortization of discount on convertible notes	(5,402)	(1,306)	(10,863)	(1,306)
Total other income (expense)	(6,698)	(1,833)	(13,470)	(1,961)
Net loss	$ (220,194)	$ (828,031)	$ (341,905)	$ (1,889,451)
Loss per share - basic and diluted	$ (0.004)	$ (0.01)	$ (0.01)	$ (0.03)
Weighted average shares outstanding - basic and diluted	56,211,756	55,784,493	55,990,775	55,370,365

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Payable [Member]	Common Stock Subject To Forfeiture [Member]	Retained Earnings [Member]	Total
Beginning balance value at Jun. 30, 2020	$ 5,398	$ 11,583,159		$ (3,147,763)	$ (8,447,159)	$ (6,365)
Beginning balance, shares at Jun. 30, 2020	53,984,004
note payable and interest at $0.014 per share	$ 180	24,981				24,981
note payable and interest, shares	1,797,192
Issuance of stock for accounts payable at $0.09 per share	$ 15	13,485				13,485
Issuance of stock for accounts payable, shares	150,000
Amortization of CRx shares				1,308,049		1,308,049
Fair value of options granted		282,116				282,116
Discount on convertible debt		38,638				38,638
Net loss					(1,889,451)	(1,889,451)
Fair value of warrants issued		252,104				252,104
Ending balance, value at Dec. 31, 2020	$ 5,593	12,194,483		(1,839,714)	(10,336,610)	23,557
Ending balance, shares at Dec. 31, 2020	55,931,196
Beginning balance value at Jun. 30, 2020	$ 5,398	11,583,159		(3,147,763)	(8,447,159)	(6,365)
Beginning balance, shares at Jun. 30, 2020	53,984,004
Common stock issued to officers						70,000
Ending balance, value at Jun. 30, 2021	$ 5,577	10,476,004	35,000	(223,255)	(10,307,101)	(13,775)
Ending balance, shares at Jun. 30, 2021	55,772,196
Beginning balance value at Dec. 31, 2020	$ 5,593	12,194,483		(1,839,714)	(10,336,610)	23,557
Beginning balance, shares at Dec. 31, 2020	55,931,196
Common stock issued to officers						$ 35,000
Common stock issued to officers, shares						500,000
Ending balance, value at Dec. 31, 2021	$ 5,677	10,545,904	35,000		(10,649,006)	$ (62,425)
Ending balance, shares at Dec. 31, 2021	56,772,196
Beginning balance value at Jun. 30, 2021	$ 5,577	10,476,004	35,000	(223,255)	(10,307,101)	(13,775)
Beginning balance, shares at Jun. 30, 2021	55,772,196
Amortization of CRx shares				223,255		223,255
Common stock issuable to officers			70,000			70,000
Common stock issued to officers	$ 100	69,900	(70,000)
Common stock issued to officers, shares	1,000,000					1,000,000
Net loss					(341,905)	$ (341,905)
Ending balance, value at Dec. 31, 2021	$ 5,677	$ 10,545,904	$ 35,000		$ (10,649,006)	$ (62,425)
Ending balance, shares at Dec. 31, 2021	56,772,196

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)	Jul. 30, 2020$ / shares
Notes Payable And Interest [Member]
Extinguishment of Debt [Line Items]
Shares issued price, per share	$ 0.014
Accounts Payable [Member]
Extinguishment of Debt [Line Items]
Shares issued price, per share	$ 0.09

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (341,905)	$ (1,889,451)
Adjustments to reconcile net loss to net cash used in operating activities
Stock based compensation		534,220
Fair value of shares issued for CRx Acquisition	223,255	1,308,049
Stock issued for services and license fee		13,500
Stock issued/issuable to officers	70,000
Discount on convertible debt	10,863	1,306
Changes is assets and liabilities
Decrease in prepaids	7,500	6,000
Increase (decrease) in accounts payable and accrued expenses	188	(14,276)
Cash used in operating activities	(30,099)	(40,652)
Cash flows from investing activities
Cash used in investing activities
Cash flows from financing activities
Cash proceeds from convertible note payable - related		78,000
Advance from officer	15,000
Cash provided by financing activities	15,000	78,000
Net increase in cash and cash equivalents	(15,099)	37,348
Cash and cash equivalents, beginning of period	18,041	10,786
Cash and cash equivalents, end of period	2,942	48,134
Supplemental disclosure of non-cash investing and financing activities
Shares issued for conversion of related party note and interest		25,161
Shares issued for settlement of accounts payable		$ 13,500

Nature of Business and Basis of

Nature of Business and Basis of Presentation	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Nature of Business and Basis of Presentation	Note 1 – Nature of Business and Basis of Presentation Nexien BioPharma, Inc. (the “Company” or “Nexien”) was incorporated in the State of Michigan on November 10, 1952 as Gantos, Inc., and was reincorporated in the State of Delaware in 2008, changing its name to Kinder Holding Corp. In October 2017, the Company completed a reverse acquisition of Intiva BioPharma Inc., a Colorado corporation (“BioPharma”), incorporated on March 27, 2017, through an exchange of shares (the “Share Exchange Transaction”) and changed its name to Intiva BioPharma Inc. In September 2018, the Company changed its name to Nexien BioPharma, Inc. As further described in Note 4, BioPharma became a wholly-owned subsidiary of the Company. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer). The operations of BioPharma were the only continuing operations of the Company. BioPharma was incorporated to pursue pre-clinical and drug development activities, in accordance with U.S. Food and Drug Administration (“FDA”) protocols, for certain pharmaceutical formulations that include cannabinoids. It is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders and medical conditions, and owns a license covering certain intellectual property, including certain patent applications, and has filed three of its own provisional patent applications for other drugs that include cannabinoids and other substances, including terpenes, that are intended to be developed with the objective of treating certain medical conditions and disorders. It was formed as a corporate subsidiary of the Colorado corporation Kanativa USA Inc. (“Kanativa USA”), which is a subsidiary of the Ontario, Canada corporation, Kanativa Inc. Principles of Consolidation The accompanying consolidated financial statements include BioPharma and its wholly owned subsidiaries: Intiva BioPharma Inc. (a Colorado corporation), NexN Inc. (“NexN”) and NexDM Inc. (collectively the “Company”), and were prepared from the accounts of the Company in accordance with accounting principles generally accepted in the United States of America (US GAAP). All significant intercompany transactions and balances have been eliminated on consolidation.

Going Concern Uncertainty

Going Concern Uncertainty	6 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Uncertainty	Note 2 - Going Concern Uncertainty The accompanying financial statements have been prepared in conformity with US GAAP, which contemplates continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception of $ 10,649,006 62,425 NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no Valuation of Long-Lived Assets The Company reviews the recoverability of its long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The Company’s primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations. Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2021 and June 30, 2021, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 3 – Summary of Significant Accounting Policies (continued) If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended December 31, 2021 and June 30, 2021, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As at December 31, 2021 and June 30, 2021, no assets or liabilities were required to be measured at fair value on a recurring basis. Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Revenue Recognition The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Research and Development Expenses Research and development expenses are charged to operations as incurred. NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 3 – Summary of Significant Accounting Policies (continued) Stock-based compensation Pursuant to FASB ASC 718, all share-based payments to employees, including grants of employee stock options, are recognized in the statement of operations based on their fair values. Issuance of shares for non-cash consideration The Company accounts for the issuance of equity instruments to acquire goods and/or services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of the standards issued by the FASB. The measurement date for the fair value of the equity instruments issued is determined as the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Reclassifications Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation. Recent Accounting Pronouncements Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial position or results of operations. Management has evaluated accounting standards and interpretations issued but not yet effective as of December 31, 2021 and does not expect such pronouncements to have a material impact on the Company’s financial position, operations, or cash flows.

Share Exchange Agreement

Share Exchange Agreement	6 Months Ended
	Dec. 31, 2021
Share Exchange Agreement
Share Exchange Agreement	Note 4 – Share Exchange Agreement On August 8, 2017, the Company entered into a Share Exchange Agreement, as amended and restated on October 13, 2017 (the “Agreement”), with BioPharma. Pursuant to the terms of the Agreement, the Company agreed to issue to the shareholders of BioPharma 42,642,712 0.0001 20,000,000

License Agreements

License Agreements	6 Months Ended
	Dec. 31, 2021
License Agreements
License Agreements	Note 5 – License Agreements Accu-Break License Agreement On February 28, 2018, the Company obtained a worldwide exclusive license with respect to a proprietary delivery system for cannabinoid-based medications from Accu-Break Pharmaceuticals Inc (Accu-Break), whose President was an affiliate of the Company as of the date of the agreement. Upon execution of the agreement, as amended September 18, 2018, $ 35,000 30,000 35,000 NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 5 – License Agreements (continued) The Company is required to pay milestone payments upon obtaining regulatory approval of pharmaceutical licensed products and royalties based upon sales of licensed products. The Company may grant sublicenses under the terms of the agreement. The Company has previously estimated that it may not be able to recover the $ 65,000 65,000 35,000

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity	Note 6– Stockholders’ Equity Common stock In May 2021, the Board of Directors authorized the issuance of a total of 2,500,000 250,000 35,000 500,000 1,000,000 70,000 During the six months ended December 31, 2020, the Company issued shares of its common stock as follows: ● 1,797,192 0.014 25,000 161 ● 150,000 13,500 0.09 CRX Limited Liability Company Interest Purchase Agreement On October 26, 2018, Company entered into a Limited Liability Company Interest Purchase Agreement (the “Purchase Agreement”) with the members of CRx Bio Holdings LLC, a Delaware limited liability company (“CRx”), to acquire all of the membership interest in CRx in exchange for 11,000,000 0.76 0 1,100,000 9,900,000 NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 6- Stockholders’ Equity (continued) Any Seller who was not then providing services to the Company or any of its subsidiaries on any vesting date, whether through voluntary termination or termination “for cause,” would forfeit his unvested shares, which would be cancelled. The transaction was valued at $ 8,360,000 11,000,000 0.76 836,000 1,100,000 7,524,000 9,900,000 0 Effective December 31, 2018, one of the Sellers resigned from the Company and forfeited 1,732,500 142,500 In March 2021, four of the Sellers terminated their relationships with the Company and forfeited their remaining 2,409,000 1,830,840 0.76 As at December 31, 2021, all shares issued were fully vested and an aggregate $ 5,104,159 223,255,000 1,308,049 2017 Stock Incentive Plan On August 10, 2017, the Company adopted the “2017 Stock Incentive Plan” and granted an aggregate of 6,400,000 800,000 0.125 1,166,667 145,833 1,083,342 5,233,333 654,167 2018 Equity Incentive Plan (i) On March 30, 2018, the Company’s board of directors approved and recommended for adoption by the stockholders of the Company a 2018 Equity Incentive Plan and has reserved 8,000,000 In July 2018, the Board of Directors granted options to purchase a total of 1,810,000 seven years 0.54 In August 2018, the Board of Directors granted options to purchase a total of 150,000 seven years 0.38 NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 6-Stockholders’ Equity (continued) The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Stock Options Assumptions Average risk-free interest rates 2.3 2.8 % Average expected life (in years) 4.0 7.0 Volatility 160 296 % (ii) On October 17, 2018, the Board of Directors granted options to purchase an aggregate 800,000 seven years 0.655 500,000 seven years 0.48 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Stock Options Assumptions Average risk-free interest rates 2.88 2.93 % Average expected life (in years) 4.0 Volatility 171 172 % (iii) On August 19, 2020, the Board of Directors authorized the issuance of an aggregate 5,000,000 0.08 seven-year 3,333,334 1,666,666 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Stock Options Assumptions Average risk-free interest rates 0 % Average expected life (in years) 4.0 Volatility 152 % The fair value of the vested options granted of $ 315,350 A summary of option activity during the six months ended December 31, 2021 is presented below: Schedule of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding and exercisable – June 30, 2021 7,995,000 $ 0.26 4.5 Granted - Exercised - Expired/Canceled - Outstanding and exercisable -December 31, 2021 7,995,000 $ 0.26 4.2 NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 6 – Stockholders’ Equity (continued) Warrants On November 24, 2020, the Company issued warrants for the acquisition of common shares as partial consideration for the issuance of convertible notes. The following table summarizes information about warrants outstanding at December 31, 2021: Schedule of Warrants Outstanding Number Exercise Price Expires Class A 1,727,299 $ 0.040265 November 24, 2025 Class B 1,727,299 $ 0.043276 November 24, 2025 Class C 1,727,299 $ 0.045157 November 24, 2025 The fair value of the warrants granted is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Warrants Assumptions Average risk-free interest rates .39 % Average expected life (in years) 2.5 Volatility 153 % The relative fair value of the warrants granted of $ 252,104

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7 – Convertible Notes Payable On November 24, 2020, the Company entered into financing agreements with two individuals, its CEO and a shareholder. Under the agreements, the Company issued unsecured convertible promissory notes due in three years November 24, 2023 8 0.037631 10 40,000 15,000 25,000 25,000 five-year 0.040265 0.043276 0.045157 5,181,897 The Company has recorded the conversion feature as a Beneficial Conversion Feature. The fair value of $ 65,000 10,863

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 – Related Party Transactions BioPharma was formed as a subsidiary of Kanativa USA, which is a subsidiary of Kanativa Inc. Kanativa USA was issued 24,000,000 100 201,228 NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 8 – Related Party Transactions (continued) In May 2021, the Company’s Board of Directors authorized the issuance of a total of 2,500,000 250,000 35,000 500,000 During the three months ended December 31, 2021, the Company’s Chief Executive Officer advanced an aggregate $ 15,000 The members of the Company’s Board of Directors, its Chief Executive Office and its Chief Financial Officer are also directors and officers of Kanativa Inc., and other subsidiaries and affiliated entities of Kanativa Inc.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9- Commitments and Contingencies At December 31, 2021, there were no legal proceedings against the Company.

Subsequent Events

Subsequent Events	6 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 10 Subsequent Events Note Purchase Agreement On January 18, 2022, the Company entered into a note purchase agreement with Quick Capital, LLC, a Wyoming limited liability company (“Quick Capital”), pursuant to which the Company issued Quick Capital a twelve-month convertible promissory note in the principal amount of $ 170,454 150,000 12 500,000 three-year 347,512 0.075 146,750 3,250 Quick Capital is entitled to a cash payment of $ 20,000 1,000,000 The Note is convertible into shares of common stock at a conversion price of $ 0.035 If an event of default (as described in the Note) occurs, the Note will become immediately due and payable in an amount equal to 150 The Note may not be converted and the Warrant may not be exercised if after giving effect to such conversion or exercise, as the case may be, Quick Capital and its affiliates would beneficially own more than 9.99 NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 10 – Subsequent Events (continued) On or after May 7, 2022 and upon the mutual agreement of the Company and Quick Capital, Quick Capital may purchase additional note(s) in an aggregate amount not to exceed $ 350,000 In connection with this transaction, the Company issued, as a consulting fee, a one-year 2,250,000 0.001 January 25, 2022 In January 2022, the Company issued an aggregate 500,000 Advance from Officer Subsequent to December 31, 2021, the Company’s Chief Executive Officer advanced an additional $ 10,000 The Company has analyzed its operations subsequent to December 31, 2021 through the date these financial statements were issued, and has determined that it does not have any additional material subsequent events to disclose.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets The Company reviews the recoverability of its long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The Company’s primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2021 and June 30, 2021, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.
Fair Value Measurements	Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. NEXIEN BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 3 – Summary of Significant Accounting Policies (continued) If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended December 31, 2021 and June 30, 2021, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As at December 31, 2021 and June 30, 2021, no assets or liabilities were required to be measured at fair value on a recurring basis.
Earnings per Common Share	Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
Income Taxes	Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.
Revenue Recognition	Revenue Recognition The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.
Research and Development Expenses	Research and Development Expenses Research and development expenses are charged to operations as incurred.
Stock-based compensation	Stock-based compensation Pursuant to FASB ASC 718, all share-based payments to employees, including grants of employee stock options, are recognized in the statement of operations based on their fair values.
Issuance of shares for non-cash consideration	Issuance of shares for non-cash consideration The Company accounts for the issuance of equity instruments to acquire goods and/or services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of the standards issued by the FASB. The measurement date for the fair value of the equity instruments issued is determined as the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.
Reclassifications	Reclassifications Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial position or results of operations. Management has evaluated accounting standards and interpretations issued but not yet effective as of December 31, 2021 and does not expect such pronouncements to have a material impact on the Company’s financial position, operations, or cash flows.

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Stock Option Activity	A summary of option activity during the six months ended December 31, 2021 is presented below: Schedule of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding and exercisable – June 30, 2021 7,995,000 $ 0.26 4.5 Granted - Exercised - Expired/Canceled - Outstanding and exercisable -December 31, 2021 7,995,000 $ 0.26 4.2
Schedule of Warrants Outstanding	The following table summarizes information about warrants outstanding at December 31, 2021: Schedule of Warrants Outstanding Number Exercise Price Expires Class A 1,727,299 $ 0.040265 November 24, 2025 Class B 1,727,299 $ 0.043276 November 24, 2025 Class C 1,727,299 $ 0.045157 November 24, 2025
Schedule of Fair Value of Warrants Assumptions	The fair value of the warrants granted is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Warrants Assumptions Average risk-free interest rates .39 % Average expected life (in years) 2.5 Volatility 153 %
August Two Thousand Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Fair Value of Stock Options Assumptions	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Stock Options Assumptions Average risk-free interest rates 2.3 2.8 % Average expected life (in years) 4.0 7.0 Volatility 160 296 %
October Two Thousand Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Fair Value of Stock Options Assumptions	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Stock Options Assumptions Average risk-free interest rates 2.88 2.93 % Average expected life (in years) 4.0 Volatility 171 172 %
August Two Thousand Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Fair Value of Stock Options Assumptions	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Stock Options Assumptions Average risk-free interest rates 0 % Average expected life (in years) 4.0 Volatility 152 %

Going Concern Uncertainty (Deta

Going Concern Uncertainty (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 10,649,006	$ 10,649,006	$ 10,307,101
Working capital	$ 15,000	$ 62,425

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 31, 2021	Jun. 30, 2021
Accounting Policies [Abstract]
Cash equivalents	$ 0	$ 0

Share Exchange Agreement (Detai

Share Exchange Agreement (Details Narrative) - $ / shares	Aug. 08, 2017	Dec. 31, 2021	Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock par value		$ 0.0001	$ 0.0001
Share Exchange Agreement [Member] | Post-Reverse Stock-Split [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock-split shares	42,642,712
Common stock par value	$ 0.0001
Share Exchange Agreement [Member] | Pre-Reverse Split [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock-split shares	20,000,000

License Agreements (Details Nar

License Agreements (Details Narrative) - USD ($)	Jun. 30, 2019	Sep. 18, 2018	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Value of common stock shares			$ 70,000		$ 35,000	$ 70,000
Accu-Break Pharmaceuticals, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Payment to license	$ 30,000	$ 35,000					$ 35,000
Accu-Break Pharmaceuticals, Inc. [Member] | License Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Capitalized cost of intangible assets								$ 65,000
Impairment of licenses								$ 65,000
Value of common stock shares							$ 35,000

Schedule of Fair Value of Stock

Schedule of Fair Value of Stock Options Assumptions (Details) - 2018 Equity Incentive Plan [Member]	Aug. 19, 2020	Oct. 17, 2018	Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rates, minimum		2.88%	2.30%
Average risk-free interest rates, maximum		2.93%	2.80%
Average expected life (in years)	4 years	4 years
Volatility, minimum		171.00%	160.00%
Volatility, maximum		172.00%	296.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.00%
Volatility	152.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average expected life (in years)			4 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average expected life (in years)			7 years

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	6 Months Ended
	Dec. 31, 2021$ / sharesshares
Equity [Abstract]
Number of shares, Outstanding and exercisable beginning balance	7,995,000
Weighted Average Exercise Price, Outstanding and exercisable beginning balance | $ / shares	$ 0.26
Weighted Average Remaining Contractual Life (Years), Outstanding and Exercisable beginning balance	4 years 6 months
Number of shares, Granted
Number of shares, Exercised
Number of shares, Expired/Canceled
Number of shares, Outstanding and exercisable ending balance	7,995,000
Weighted Average Exercise Price, Outstanding and Exercisable ending balance | $ / shares	$ 0.26
Weighted Average Remaining Contractual Life (Years), Outstanding and Exercisable ending balance	4 years 2 months 12 days

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	Dec. 31, 2021$ / sharesshares
Class A Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding | shares	1,727,299
Exercise price of warrants | $ / shares	$ 0.040265
Expiration date of warrants	Nov. 24, 2025
Class B Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding | shares	1,727,299
Exercise price of warrants | $ / shares	$ 0.043276
Expiration date of warrants	Nov. 24, 2025
Class C Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding | shares	1,727,299
Exercise price of warrants | $ / shares	$ 0.045157
Expiration date of warrants	Nov. 24, 2025

Schedule of Fair Value of Warra

Schedule of Fair Value of Warrants Assumptions (Details)	Dec. 31, 2021
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input for warrants, percentage	0.39
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input, term, warrants	2 years 6 months
Measurement Input, Option Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input for warrants, percentage	153

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

Aug. 19, 2020

Oct. 26, 2018

Oct. 17, 2018

Oct. 02, 2018

Aug. 19, 2018

Jul. 25, 2018

Aug. 10, 2017

May 31, 2021

Mar. 31, 2021

May 31, 2019

Aug. 31, 2018

Jul. 31, 2018

Mar. 31, 2018

Sep. 30, 2021

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2018

Dec. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Mar. 30, 2018

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number of common stock shares issued

1,000,000

500,000

Value of common stock shares

$ 70,000

$ 35,000

$ 70,000

Stock price per share

$ 0.09

Stock issued for service

150,000

Stock issued during period value issued for services

$ 13,500

Stockholder's equity

$ (62,425)

23,557

(62,425)

(13,775)

$ (6,365)

Number of options issued

Fair value of warrants

$ 252,104

2018 Equity Incentive Plan [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Share based compensation stock options, vested

1,666,666

Common stock reserved for issuance

8,000,000

Purchase Agreement [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Share based compensation stock options, vested

142,500

CRX Limited Liability Company [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Stock price per share

$ 0.76

Unvested forfeited, shares

2,409,000

Unvested forfeited, amount

$ 1,830,840

Value of vested shares issued and amortization of unvested shares

5,104,159

$ 5,104,159

Amortization expenses

$ 223,255,000

$ 1,308,049

CRX Limited Liability Company [Member] | Interest Purchase Agreement [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Stock price per share

$ 0.76

$ 0.76

Number of common stock restricted shares

11,000,000

11,000,000

Fair value of common stock issued for asses acquisition

$ 0

Number of common stock restricted shares forfeited

1,100,000

1,100,000

Share based compensation stock options, vested

9,900,000

9,900,000

Fair value of stock issued for acquisition

$ 8,360,000

Fair value of shares issued

$ 836,000

Fair value of stock option, vested

7,524,000

Stockholder's equity

$ 0

Unvested forfeited, shares

1,732,500

Board of Directors [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number of common stock shares issued

2,500,000

Stock issued for service

2,500,000

Board of Directors [Member] | 2018 Equity Incentive Plan [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Share based compensation stock options, vested

3,333,334

Fair value of stock option, vested

$ 315,350

Number of options issued

5,000,000

Options exercisable

$ 0.08

Chief Executive Officer and Chief Financial Officer [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number of common stock shares issued

250,000

Number of unvested shares of common stock

1,083,342

Chief Executive Officer [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number od stock conversion

1,797,192

Stock price per share

$ 0.014

Principal amount

$ 25,000

Accrued interest

$ 161

Five Officers and Directors [Member] | 2017 Stock Incentive Plan [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number of common stock shares issued

6,400,000

Value of common stock shares

$ 800,000

Stock price per share

$ 0.125

Former Chief Executive Officer [Member] | 2017 Stock Incentive Plan [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Unvested forfeited, shares

5,233,333

1,166,667

Unvested forfeited, amount

$ 654,167

$ 145,833

Officers / Directors / Consultants [Member] | 2018 Equity Incentive Plan [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number of options to purchase shares of common stock

1,810,000

Options exercisable term

7 years

Options exercise price per share

$ 0.54

Two Individuals [Member] | 2018 Equity Incentive Plan [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number of options to purchase shares of common stock

150,000

Options exercisable term

7 years

Options exercise price per share

$ 0.38

Officers / Directors [Member] | 2018 Equity Incentive Plan [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]

Number of options to purchase shares of common stock

800,000

500,000

Options exercisable term

7 years

7 years

Options exercise price per share

$ 0.655

$ 0.48

Options exercisable term

seven-year

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	Nov. 24, 2020USD ($)d$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / shares	Oct. 31, 2020USD ($)
Short-term Debt [Line Items]
Stock price per share			$ 0.09		$ 0.09
Amortization of convertible notes | $		$ 5,402	$ 1,306	$ 10,863	$ 1,306
Class A Warrants [Member]
Short-term Debt [Line Items]
Exercise price of warrants		$ 0.040265		$ 0.040265
Number of warrants outstanding | shares		1,727,299		1,727,299
Class B Warrants [Member]
Short-term Debt [Line Items]
Exercise price of warrants		$ 0.043276		$ 0.043276
Number of warrants outstanding | shares		1,727,299		1,727,299
Class C Warrants [Member]
Short-term Debt [Line Items]
Exercise price of warrants		$ 0.045157		$ 0.045157
Number of warrants outstanding | shares		1,727,299		1,727,299
Chief Executive Officer [Member]
Short-term Debt [Line Items]
Stock price per share			$ 0.014		$ 0.014
Lending amount | $			$ 25,000		$ 25,000
Financing Arrangement [Member]
Short-term Debt [Line Items]
Fair value of notes payable | $	$ 65,000
Financing Arrangement [Member] | Chief Executive Officer And Shareholder [Member] | Class A Warrants [Member]
Short-term Debt [Line Items]
Exercise price of warrants	$ 0.040265
Financing Arrangement [Member] | Chief Executive Officer And Shareholder [Member] | Class B Warrants [Member]
Short-term Debt [Line Items]
Exercise price of warrants	0.043276
Financing Arrangement [Member] | Chief Executive Officer And Shareholder [Member] | Class C Warrants [Member]
Short-term Debt [Line Items]
Exercise price of warrants	$ 0.045157
Financing Arrangement [Member] | Chief Executive Officer And Shareholder [Member] | Warrant [Member]
Short-term Debt [Line Items]
Warrants exercisable period	5 years
Number of warrants outstanding | shares	5,181,897
Financing Arrangement [Member] | Chief Executive Officer And Shareholder [Member] | Unsecured Convertible Promissory Notes [Member]
Short-term Debt [Line Items]
Debt maturity term	3 years
Debt maturity date	Nov. 24, 2023
Debt interest rate	8.00%
Stock price per share	$ 0.037631
Trading days | d	10
Financing Arrangement [Member] | Chief Executive Officer [Member]
Short-term Debt [Line Items]
Lending amount | $	$ 40,000
Advance amount | $	25,000					$ 15,000
Additional loan | $	$ 25,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2021	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2021
Restructuring Cost and Reserve [Line Items]
Number of common stock shares issued				1,000,000		500,000
Number of common stock shares issued for services, shares					150,000
Fair value of number of shares			$ 70,000			$ 35,000	$ 70,000
Working capital		$ 15,000		$ 62,425
Board of Directors [Member]
Restructuring Cost and Reserve [Line Items]
Number of common stock shares issued	2,500,000
Number of common stock shares issued for services, shares	2,500,000
Chief Financial Officer [Member]
Restructuring Cost and Reserve [Line Items]
Number of common stock shares issued for services, shares	250,000
Individuals [Member]
Restructuring Cost and Reserve [Line Items]
Number of common stock shares issued				500,000
Fair value of number of shares				$ 35,000
BioPharma [Member]
Restructuring Cost and Reserve [Line Items]
Number of common stock shares issued				24,000,000
Ownership percentage		100.00%		100.00%		100.00%
BioPharma and NexN [Member]
Restructuring Cost and Reserve [Line Items]
Related party expenses				$ 201,228

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 18, 2022	Jan. 31, 2022	May 07, 2022	Jan. 02, 2022	Dec. 31, 2020
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Aggregate amount					$ 25,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants term			1 year
Conversion price	$ 0.035
Subsequent Event [Member] | Eyed Jack Enterprises L L C [Member]
Subsequent Event [Line Items]
Consulting fees			2,250,000
Exercise price			$ 0.001
Warrant exercised date	Jan. 25, 2022
Subsequent Event [Member] | Two Officers [Member]
Subsequent Event [Line Items]
Shares issued for compensation		500,000
Subsequent Event [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Advance from officer				$ 10,000
Subsequent Event [Member] | Quick Capital LLC [Member]
Subsequent Event [Line Items]
Cash payment	$ 20,000
Debt securities	$ 1,000,000
Outstanding common stock	9.99%
Subsequent Event [Member] | Quick Capital LLC [Member] | Convertible Debt [Member]
Subsequent Event [Line Items]
Interest rate	150.00%
Subsequent Event [Member] | Note Purchase Agreement [Member] | Quick Capital LLC [Member]
Subsequent Event [Line Items]
Aggregate amount	$ 170,454
Investments	$ 150,000
Original issuane discount	12.00%
Restricted share	500,000
Warrants term	3 years
Exercise price	$ 0.075
Proceed from issuance of debt	$ 146,750
Legal fees	$ 3,250
Subsequent Event [Member] | Note Purchase Agreement [Member] | Quick Capital LLC [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Consulting fees	347,512
Subsequent Event [Member] | Mutual Agreement [Member]
Subsequent Event [Line Items]
Aggregate amount			$ 350,000